Filtered By:
Condition: Pulmonary Thromboembolism

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 2761 results found since Jan 2013.

Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery
CONCLUSIONS: In some types of elective surgery, cell salvage may reduce the need for and volume of allogeneic transfusion, alongside evidence of no difference in adverse events, when compared to no cell salvage. Further research is required to establish why other surgeries show no benefit from CS, through further analysis of the current evidence. More large RCTs in under-reported specialities are needed to expand the evidence base for exploring the impact of CS.PMID:37681564 | PMC:PMC10486190 | DOI:10.1002/14651858.CD001888.pub5
Source: Cochrane Database of Systematic Reviews - September 8, 2023 Category: General Medicine Authors: Thomas D Lloyd Louise J Geneen Keeley Bernhardt William McClune Scott J Fernquest Tamara Brown Carolyn Dor ée Susan J Brunskill Michael F Murphy Antony Jr Palmer Source Type: research

Rivaroxaban: an oral factor xa inhibitor.
CONCLUSIONS: Based on the findings of the studies reported in this review, rivaroxaban is an effective option for the prevention of VTE after orthopedic surgery, stroke prevention for nonvalvular AF, and treatment of VTE. At this time, rivaroxaban cannot be recommended for secondary risk reduction after ACS because of the increased bleeding risk. PMID: 23328267 [PubMed - in process]
Source: Clinical Therapeutics - January 1, 2013 Category: Drugs & Pharmacology Authors: Thomas TF, Ganetsky V, Spinler SA Tags: Clin Ther Source Type: research

Antithrombotic Therapy for Prevention of Various Thrombotic Diseases
Abstract The majority of sudden onset serious diseases, such as acute myocardial infarction, ischemic stroke, and pulmonary embolism, are thrombotic diseases. Antithrombotic therapy in general has a potential to reduce the risk of thrombotic diseases, though it increases the risk of serious bleeding events. Of the various antithrombotic agents currently available, the antiplatelet agent aspirin and the anticoagulant agent warfarin have the most robust clinical evidence. Aspirin reduces the risk of cardiovascular (CV) death, recurrence of myocardial infarction and ischemic stroke by up to 25%. Aspirin is an establish...
Source: Drug Development Research - November 15, 2013 Category: Drugs & Pharmacology Authors: Shinya Goto, Aiko Tomita Tags: Clinical Overview Source Type: research

Hormone therapy for preventing cardiovascular disease in post-menopausal women.
CONCLUSIONS: Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall, for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events. PMID: 25754617 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 10, 2015 Category: Journals (General) Authors: Boardman HM, Hartley L, Eisinga A, Main C, Roqué I Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B Tags: Cochrane Database Syst Rev Source Type: research

Transient ischemic attacks in post-menopausal women with history of migraines have lower risk for subsequent ischemic strokes (P2.306)
CONCLUSIONS: The risk of ischemic stroke is lower following TIA in women with migraine history (compared with those without migraine) suggesting potentially different pathophysiology in such women.Disclosure: Dr. Rahman has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Thomas has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Rahman, H., Malik, A., Thomas, A., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Education and TIA Source Type: research

A pulmonary vein thrombus in a patient with autonomic nervous dysfunction
Publication date: Available online 8 May 2015 Source:IJC Heart & Vasculature Author(s): Hidekazu Takeuchi Ischemic stroke is a serious clinical problem, and preventing ischemic stroke is an important clinical target. Left atrial thrombus is a known cause of ischemic stroke. In 2015, I reported that nearly all left atrial thrombi result from a pulmonary vein thrombus (PVT), indicating that PVT is associated with ischemic stroke. However, the relationship between PVT and autonomic nervous function is unknown. Although PVT is believed to be rare, since 2012, I have reported several cases of PVT in elderly patients w...
Source: IJC Heart and Vasculature - May 9, 2015 Category: Cardiology Source Type: research

Global Burden of Thrombosis: Epidemiologic Aspects.
Abstract Thromboembolic conditions were estimated to account for 1 in 4 deaths worldwide in 2010 and are the leading cause of mortality. Thromboembolic conditions are divided into arterial and venous thrombotic conditions. Ischemic heart disease and ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise venous thromboembolism. Atrial fibrillation is a major risk factor for stroke and systemic arterial thromboembolism. Estimates of the global burden of disease were obtained from Global Burden of Disease Project reports, recent systematic reviews, and searchin...
Source: Circulation Research - April 28, 2016 Category: Cardiology Authors: Wendelboe AM, Raskob GE Tags: Circ Res Source Type: research

Left atrial appendage closure for prevention of cardioembolic events.
We describe the pathophysiology of the LAA with regard to stroke. Aside from the evidence and limitations of anticoagulation as the classical treatment paradigm for stroke prevention, devices and techniques for LAAC are outlined and the current clinical evidence with regard to efficacy and safety is reviewed. Finally, contemporary recommendations for patient selection are provided. PMID: 27244534 [PubMed - as supplied by publisher]
Source: Swiss Medical Weekly - June 1, 2016 Category: Journals (General) Authors: Gloekler S, Meier B, Windecker S Tags: Swiss Med Wkly Source Type: research

High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
CONCLUSION: Patients with AAV have a high incidence of arterial and venous thrombosis, particularly in the first year after diagnosis. PMID: 30385704 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - November 3, 2018 Category: Rheumatology Tags: J Rheumatol Source Type: research

A Serious Diagnosis Lacking Common Symptoms
​BY JENNIFER TUONG; IVAN KHARCHENKO; JEAN LUC AGARD; & AHMED RAZIUDDIN, MDA 65-year-old man who had HIV well-controlled with highly active antiretroviral therapy, hypertension, sciatica, and restless leg syndrome presented to the emergency department with left leg pain. He also had had chemotherapy and radiation for anal cancer. The patient said the pain had started 45 minutes earlier when he was sitting on the toilet.He described the pain as sore in quality and 10/10 on the pain scale. He reported that it had started in his lower back and radiated to his left leg. He said he had had no trauma or weakness to the regi...
Source: The Case Files - May 28, 2019 Category: Emergency Medicine Tags: Blog Posts Source Type: research

Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease
Conclusions: CaD did not consistently modify the effect of CEE therapy or CEE + MPA therapy on CVD events. However, the increased risk of stroke due to CEE therapy appears to be mitigated by CaD supplementation. In contrast, CaD supplementation did not influence the risk of stroke due to CEE + MPA.
Source: Menopause - August 1, 2019 Category: OBGYN Tags: Original Articles Source Type: research

One-stop strategy for treatment of atrial fibrillation: feasibility and safety of combining catheter ablation and left atrial appendage closure in a single procedure.
CONCLUSIONS: Combining catheter ablation and LAAC in a single procedure can be successfully and safely performed in non-valvular AF patients of Chinese population. PMID: 32433041 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - May 17, 2020 Category: General Medicine Authors: Chen M, Wang ZQ, Wang QS, Sun J, Zhang PP, Feng XF, Li W, Yu Y, Liu B, Mo BF, Zhang R, Yang M, Gong CQ, Zhao MZ, Yu YC, Zhao Y, Lu QF, Li YG Tags: Chin Med J (Engl) Source Type: research

Anticoagulation versus placebo for heart failure in sinus rhythm
CONCLUSIONS: Based on the three RCTs, there is no evidence that oral anticoagulant therapy modifies mortality in people with HF in sinus rhythm. The evidence is uncertain if warfarin has any effect on all-cause death compared to placebo or no treatment, but it may increase the risk of major bleeding events. There is no evidence of a difference in the effect of rivaroxaban on all-cause death compared to placebo. It probably reduces the risk of stroke, but probably increases the risk of major bleedings. The available evidence does not support the routine use of anticoagulation in people with HF who remain in sinus rhythm.PMI...
Source: Cochrane Database of Systematic Reviews - May 18, 2021 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł Gregory Yh Lip Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news